Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Winter;11(Suppl 1):S39-S44.

Determining the degree of adherence to treatment in inflammatory bowel disease patients

Hedieh Balaii  1 , Sepideh Olyanasab Narab  2 , Binazir Khanabadi  3 , Fakhri Alsadat Anaraki  4 , Shabnam Shahrokh  2
Affiliations

Determining the degree of adherence to treatment in inflammatory bowel disease patients

Hedieh Balaii et al. Gastroenterol Hepatol Bed Bench. 2018 Winter.

Abstract

Aim: Since the inflammatory bowel disease (IBD) is a disorder which requires continuous drug intake to induce and maintain the remission phase, finding the barriers for low adherent group, may improve the disease phase and quality of life in those patients.

Background: IBD is defined as a chronic immune disorder with unpredictable flares. The common treatment of these diseases can be effective for inducing and maintaining remission courses. Therefore the use of long-term medication therapy is the crucial key to prevent surgery and complications in patients with IBD.

Methods: Morisky Medication Adherence Scales (MMAS) is used for detecting level of adherence to the medicines for 137 patients with IBD. Demographic and clinical data are recorded for all patients and quality of life has been evaluated by Short-Form 36 questionnaire in 55 patients.

Results: Demographic and clinical features showed no correlation with the degree of adherence. The MMAS-8 score in the low adherent group significantly different than that in the medium and high adherer group. No relation was found statistically between level of adherence and mental or physical sates (p value=0.17, 1.2) and total quality of life (p value=0.22) in patients with IBD.

Conclusion: Designing smart reminder and the physician's explain about adverse effects and beneficial of medicines may be effective to confront with forgetfulness and feeling comfort with treatment. Improve a strategy in order to regular measurement of adherence to medication, provides enough information about stop taking medication.

Keywords: Adherence; Crohn’s disease; Inflammatory bowel disease; Quality of life; Ulcerative colitis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Sewitch MJ, Abrahamowicz M, Barkun A, Bitton A, Wild GE, Cohen A, et al. Patient nonadherence to medication in inflammatory bowel disease. AJG. 2003;98:1535–44. - PubMed
    1. Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. AJM. 2003;114:39–43. - PubMed
    1. Dadaei T, Safapoor MH, Asadzadeh Aghdaei H, Balaii H, Pourhoseingholi MA, Naderi N, et al. Effect of vitamin D3 supplementation on TNF-α serum level and disease activity index in Iranian IBD patients. Gastroenterol Hepatol Bed Bench. 2015;8:49–55. - PMC - PubMed
    1. Higgins PD, Rubin D, Kaulback K, Schoenfield P, Kane S. Systematic review: impact of non‐adherence to 5‐aminosalicylic acid products on the frequency and cost of ulcerative colitis flares. Aliment pharmacol Ther. 2009;29:247–57. - PubMed
    1. Taghipour N, Molaei M, Mosaffa N, Rostami-Nejad M, Asadzadeh Aghdaei H, Anissian A, et al. An experimental model of colitis induced by dextran sulfate sodium from acute progresses to chronicity in C57BL/6: correlation between conditions of mice and the environment. Gastroenterol Hepatol Bed Bench. 2016;9:45–52. - PMC - PubMed

LinkOut - more resources